SPIRIT III Data At EuroPCR Meeting Bodes Well For Abbott, Boston Scientific
This article was originally published in The Gray Sheet
Executive Summary
Abbott and Boston Scientific are encouraged by new long-term data on their Xience V/Promus drug-eluting stent that was highlighted in the late-breaking trial results presented at the recent EuroPCR conference in Barcelona